ArticleStroke2023
Anti-Epileptic Drug Target Perturbation and Intracranial Aneurysm Risk: Mendelian Randomization and Colocalization Study.
Article in Stroke, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The landscape of the methodology in drug repurposing using human genomic data: a systematic review.Briefings in bioinformatics · 2024Pooled it
- DNA methylation-estimated phenotypes, telomere length, aging and risk of intracranial aneurysms: Evidence from genetic studies.IBRO neuroscience reports · 2026Article
- Multi-Omics Genome-Wide to Explore the Formation and Development Targets for Intracranial Aneurysms.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Deciphering the interplay between SGLT2 inhibition, CCL4, and angina pectoris: A Mendelian randomization study.Medicine · 2026Article
- MICA and CYTH4 as immunological biomarkers of intracranial aneurysm: a study integrating RNA sequencing, single-cell sequencing and Mendelian randomization.Functional & integrative genomics · 2026Article
- Morphological risk factors of parent arteries in intracranial aneurysm formation: an interpretable machine learning analysis.Neuroradiology · 2026Article
- Time to Consider Pharmacologic Management of Unruptured Intracranial Aneurysms?Journal of stroke · 2025Review
- Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization.Diabetology & metabolic syndrome · 2025Article
- SGLT2 inhibition mitigates intracerebral hemorrhage risk by modulating inflammation.Scientific reports · 2025Article
- Genetic insights into SGLT2 inhibition and atrial fibrillation: exploring the mediating role of inflammatory proteins.Cardiology journal · 2025Article
- Drug classes affecting intracranial aneurysm risk: Genetic correlation and Mendelian randomization.European stroke journal · 2024Article
- Circulating lipids, lipid-lowering drug targets, and breast cancer risk: Comprehensive evidence from Mendelian randomization and summary data-based Mendelian randomization.Cancer causes & control : CCC · 2024Article
- Cerebral small vessel disease increases risk for epilepsy: a Mendelian randomization study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Gene Commonality in Arterial Circuits Throughout the Body.Aorta (Stamford, Conn.) · 2024Article
- Genetic associations in ankylosing spondylitis: circulating proteins as drug targets and biomarkers.Frontiers in immunology · 2024Article
- Effect of smoking cessation medications on intracranial aneurysm risk: A Mendelian randomization study.Tobacco induced diseases · 2024Article
- Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization study.Frontiers in pharmacology · 2024Article
- Risk factor synergism in aneurysmal subarachnoid hemorrhage: a cross-sectional study.Acta neurochirurgica · 2023Article
- SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.Cardiovascular diabetology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundIn a genome-wide association study of intracranial aneurysms (IA), enrichment was found between genes associated with IA and genes encoding targets of effective anti-epileptic drugs. Our aim was to assess if this pleiotropy is driven by shared disease mechanisms that could potentially highlight a treatment strategy for IA.
methodsUsing 2-sample inverse-variance weighted Mendelian randomization and genetic colocalization analyses we assessed: (1) if epilepsy liability in general affects IA risk, and (2) whether changes in gene- and protein-expression levels of anti-epileptic drug targets in blood and arterial tissue may causally affect IA risk.
resultsWe found no overall effect of epilepsy liability on IA. Expression of 21 genes and 13 proteins corresponding to anti-epileptic drug targets supported a causal effect (
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.